We are live on ! Find out more
ARLZ

Aralez Pharmaceuticals Inc.
ARLZ

Delisted

ARLZ was delisted on the 20th of August, 2018.

Back to rankings

59 hedge funds and large institutions have $29.6M invested in Aralez Pharmaceuticals Inc. in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more capital invested

Capital invested by funds: $21.5M → $29.6M (+$8.12M)

21% more call options, than puts

Call options by funds: $386K | Put options by funds: $320K

0% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 15

18% less funds holding

Funds holding: 72 → 59 (-13)

63% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 16

Holders
59
Holders Change
-13
Holders Change %
-18.06%
% of All Funds
1.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
15
Reduced
15
Closed
16
Calls
$386K
Puts
$320K
Net Calls
+$66K
Net Calls Change
+$137K

Top Buyers

Rank Fund Capital Flow
1
BAS
Brown Advisory Securities
Maryland
+$230K
2
Wells Fargo
Wells Fargo
California
+$152K
3
BP
Ballentine Partners
Massachusetts
+$66.9K
4
PPA
Parametric Portfolio Associates
Washington
+$51.3K
5
VF
Virtu Financial
New York
+$39.4K

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$2.75M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$360K
3
IECM
Intrinsic Edge Capital Management
Illinois
-$270K
4
UBS Group
UBS Group
Switzerland
-$146K
5
SCA
Salient Capital Advisors
Texas
-$135K
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
1
PAR Capital Management
Massachusetts
$14.7M – – –
DM
2
Deerfield Management
New York
$3.77M – – –
BlackRock
3
BlackRock
New York
$2.28M +$11.8K +8,838 +0.9%
Deutsche Bank
4
Deutsche Bank
Germany
$1.48M -$80.9K -60,447 -9%
GCP
5
GSA Capital Partners
United Kingdom
$1.07M -$97.7K -73,000 -13%
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$714K -$2.9K -2,165 -0.7%
JAM
7
JW Asset Management
Florida
$663K -$40.2K -30,000 -9%
Wells Fargo
8
Wells Fargo
California
$625K +$152K +113,720 +71%
CIM
9
Contrarius Investment Management
Jersey
$495K – – –
BAS
10
Brown Advisory Securities
Maryland
$394K +$230K +172,000 New
IP
11
Isthmus Partners
Wisconsin
$368K +$8.17K +6,104 +4%
BMCM
12
Bryn Mawr Capital Management
Pennsylvania
$260K +$22.9K +17,147 +18%
SM
13
Salzhauer Michael
$243K – – –
California Public Employees Retirement System
14
California Public Employees Retirement System
California
$242K – – –
Goldman Sachs
15
Goldman Sachs
New York
$231K +$5.09K +3,805 +4%
FSA
16
Franklin Street Advisors
North Carolina
$227K – – –
Susquehanna International Group
17
Susquehanna International Group
Pennsylvania
$227K +$1.79K +1,341 +1%
BP
18
Ballentine Partners
Massachusetts
$183K +$66.9K +50,000 +167%
Macquarie Group
19
Macquarie Group
Australia
$160K – – –
JMPWA
20
JP Morgan Private Wealth Advisors
California
$137K – – –
Bank of New York Mellon
21
Bank of New York Mellon
New York
$125K +$3.71K +2,769 +5%
Northern Trust
22
Northern Trust
Illinois
$120K -$8.81K -6,583 -11%
Morgan Stanley
23
Morgan Stanley
New York
$110K -$73.8K -55,168 -54%
PPA
24
Parametric Portfolio Associates
Washington
$88K +$51.3K +38,349 New
ProShare Advisors
25
ProShare Advisors
Maryland
$86K +$5.16K +3,853 +11%
1
2 3

ARLZ Hedge Fund Activity: Q3 2017 in Review

59 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Aralez Pharmaceuticals Inc. (ARLZ) for Q3 2017, worth a combined $29.6M — up 38% from $21.5M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of ARLZ and 6 opened new positions — a net loss of 10 holders — while 15 trimmed existing stakes and 15 added.

The largest buyer was Brown Advisory Securities, opening a new position worth an estimated $230K. The largest seller was Broadfin Capital, exiting entirely with an estimated $2.75M sold.

  • 59 institutional investors held Aralez Pharmaceuticals Inc. (ARLZ) as of Q3 2017, down from 72 in Q2 2017.
  • Funds reported $29.6M of Aralez Pharmaceuticals Inc. stock for Q3 2017, up 38% quarter-over-quarter.
  • 6 funds opened new Aralez Pharmaceuticals Inc. positions in Q3 2017 and 16 closed out, a net change of -10 holders.
  • The largest Aralez Pharmaceuticals Inc. buyer in Q3 2017 was Brown Advisory Securities, an estimated $230K added.
  • The largest Aralez Pharmaceuticals Inc. seller in Q3 2017 was Broadfin Capital, an estimated $2.75M sold.

Based on aggregated 13F filings for Q3 2017.